Hypoxia-induced RBBP7 promotes esophagus cancer progression by inducing CDK4 expression

Hypoxia-induced epigenetic regulation calls for more effective therapeutic targets for esophageal cancer. We used GEPIA and UALCAN databases to screen survival-related and cancer stage-associated genes. Eca109 and KYSE450 esophageal cancer cell lines were cultured under normoxia, hypoxia, or CoCl 2-induced hypoxia conditions, which were further transfected with plasmids expressing RB binding protein 7 (RBBP7), hypoxia-inducible factor 1 (HIF1)-α, or RBBP7 shRNA. Colony formation and MTT assays were used to detect cell proliferation. Tumor sphere formation and stemness marker detection were applied to assess cell stemness. RT-PCR and western blot analysis were used to detect the relative mRNA level and protein expression, respectively. Luciferase assay was utilized to detect the direct interaction between HIF1α and RBBP7. Up-regulated RBBP7 was identified as one of the most prominent survival-related genes, which is negatively correlated with the overall survival (OS), disease recurrence-free survival (DFS), and tumor stages. Hypoxia-induced HIF1α up-regulates RBBP7 expression, which promotes esophagus cancer cell viability, proliferation, and stemness with increased cyclin-dependent kinase 4 (CDK4) expression. Luciferase reporter assay verified that HIF1α transcriptionally regulates the expression of RBBP7. We conclude that hypoxia induces high expression of RBBP7 which is at least partially mediated by HIF1α, up-regulates the expression of downstream CDK4, and thereby promotes tumor progression in esophageal cancer cells.

[1]  C. Xing,et al.  Multivariable analysis for complete resection rate of 10-20 mm non-metastatic rectal neuroendocrine tumors: a retrospective clinical study , 2021 .

[2]  M. Ma,et al.  Circular RNA hsa_circ_0006168 contributes to cell proliferation, migration and invasion in esophageal cancer by regulating miR-384/RBBP7 axis via activation of S6K/S6 pathway. , 2020, European review for medical and pharmacological sciences.

[3]  J. Iqbal,et al.  Potential phytochemicals in the prevention and treatment of esophagus cancer: A green therapeutic approach , 2019, Pharmacological reports : PR.

[4]  P. Zhang,et al.  RBBP7 is a prognostic biomarker in patients with esophageal squamous cell carcinoma , 2018, Oncology letters.

[5]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[6]  Inkyung Jung,et al.  Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes , 2017, The Journal of Biological Chemistry.

[7]  A. Bass,et al.  CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma , 2017, Nature Communications.

[8]  N. Ahuja,et al.  Epigenetic therapy in gastrointestinal cancer: the right combination , 2016, Therapeutic advances in gastroenterology.

[9]  A. Bardia,et al.  Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. , 2016, Discovery medicine.

[10]  Zuo-min Zhou,et al.  Rbbp7 Is Required for Uterine Stromal Decidualization in Mice1 , 2015, Biology of reproduction.

[11]  W. Hung,et al.  Ras induces experimental lung metastasis through up-regulation of RbAp46 to suppress RECK promoter activity , 2015, BMC Cancer.

[12]  M. Malumbres.  Cyclin-dependent kinases , 2014, Genome Biology.

[13]  H. Kato,et al.  Treatments for esophageal cancer: a review , 2013, General Thoracic and Cardiovascular Surgery.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[16]  E. Oki,et al.  Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. , 2008, Surgery.

[17]  Zhaoyi Wang,et al.  Constitutive expression of RbAp46 induces epithelial-mesenchymal transition in mammary epithelial cells. , 2006, Anticancer research.

[18]  D. Schrump,et al.  Novel molecular targeted therapy for esophageal cancer , 2005, Journal of surgical oncology.

[19]  K. Ball,et al.  Docking-Dependent Regulation of the Rb Tumor Suppressor Protein by Cdk4 , 2004, Molecular and Cellular Biology.

[20]  B. Loggie,et al.  Inducible expression of RbAp46 activates c-Jun NH2-terminal kinase-dependent apoptosis and suppresses progressive growth of tumor xenografts in nude mice. , 2003, Anticancer research.

[21]  Zhaoyi Wang,et al.  Overexpression of RbAp46 facilitates stress‐induced apoptosis and suppresses tumorigenicity of neoplastigenic breast epithelial cells , 2003, International journal of cancer.

[22]  J. Sedivy,et al.  Regulation of cyclin-Cdk activity in mammalian cells , 2002, Cellular and Molecular Life Sciences CMLS.

[23]  G. Li,et al.  Rb-associated protein 46 (RbAp46) inhibits transcriptional transactivation mediated by BRCA1. , 2001, Biochemical and biophysical research communications.